Article Text
Statistics from Altmetric.com
Q In patients with a history of ischaemic cerebrovascular disease, does dipyridamole given with or without aspirin reduce the risk of recurrent stroke?
Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Internal medicine ★★★★★★☆ Neurology ★★★★☆☆☆ Haematology ★★★★☆☆☆
METHODS
Data sources:
Cochrane Library (Issue 4, 2002), Medline (1966–2001), EMBASE/Excerpta Medica (1980–2002), Web of Science (1981–2002), bibliographies of relevant articles, researchers, and a manufacturer of dipyridamole (Boehringer Ingelheim, Ingelheim, Germany).
Study selection and assessment:
randomised controlled trials (RCTs) in any language that evaluated dipyridamole for secondary prevention of stroke in patients with previous cerebrovascular disease. Study quality was assessed using criteria that included method of randomisation, concealment of allocation, completeness of follow up, and blinding of outcome assessment.
Outcomes:
recurrent stroke (combined fatal and non-fatal), non-fatal stroke, combined fatal and non-fatal myocardial infarction (MI), vascular death, and a composite outcome of non-fatal stroke, non-fatal MI, and vascular death.
MAIN RESULTS
5 RCTs (n = 11 240) (mean age 65 y, 60% men) were included in …
Footnotes
-
For correspondence: Professor P Bath, University of Nottingham, Nottingham, UK. Philip.bathnottingham.ac.uk
-
Source of funding: no external funding.